Caba stock forecast 2025 consensus on "CABA stock forecast

Consensus on "CABA stock forecast 2025" remains moderately bullish, underpinned by anticipated partnerships with pharmaceutical majors. Such collaborations could expand market reach and reinforce earnings growth guidance. Explore Cabaletta Bio's Fair Values from the Community and select yours The most recent analyst rating on (CABA) stock is a Buy with a $26.00 price target. To see the full list of analyst forecasts on Cabaletta Bio stock, see the CABA Stock Forecast page . Investors tracking the "CABA stock forecast 2025" see strong upside potential if the company secures regulatory approvals for its gene therapy pipeline. Institutional buying patterns since Q1 2024 have indicated growing confidence, with projected revenue increases aligning with sector-wide biotech growth rates.